New combo therapy offers hope for tough leukemia cases

This study tests a new treatment for adults with a type of leukemia (T-ALL) that has come back or not responded to standard therapy. The treatment combines an immunotherapy drug (PD-1 inhibitor) with a targeted drug (venetoclax) and chemotherapy. The goal is to see if this combination can help more patients achieve remission and improve survival, with the possibility of a stem cell transplant afterward.